140 filings
Page 4 of 7
6-K
skubo7kef j3x2jp3gcl
8 Sep 22
Medicenna to Present at Investor and Scientific Conferences in September
5:19pm
6-K
4q7e rt9r5hcn49l
22 Aug 22
Current report (foreign)
11:39am
6-K
rna5ek yoimd
22 Aug 22
Form 51-102F3 Material Change Report
9:59am
6-K
kctfon6u
15 Aug 22
Interim Condensed Consolidated Statements of Financial Position
8:00am
6-K
pxrg58s7wapfhyepqzi0
11 Aug 22
Medicenna Announces Closing of Public Offering of Units
4:36pm
6-K
0fcvr25y
11 Aug 22
Current report (foreign)
12:53pm
6-K
z3981g sjzo2qto0r
9 Aug 22
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units
9:22am
6-K
0ts5q360g8vir 66u
9 Aug 22
Medicenna Announces Pricing of US$20 Million Public Offering of Units
12:00am
6-K
t26rw ke2r0q01dpcz
5 Aug 22
Current report (foreign)
7:59am
6-K
778nbakx77280wy07e7
27 Jul 22
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
8:06am
6-K
uu2bcp
22 Jun 22
Current report (foreign)
8:00am
6-K
qho27a
22 Jun 22
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
7:15am
6-K
jg0s6ul8yz65v e7pb
9 Jun 22
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent
7:39am
6-K
ldevq5rhd y5u9vj99c9
7 Jun 22
Current report (foreign)
9:12am
6-K
h2d2lfwvxipkmwt0ufn
11 May 22
Current report (foreign)
8:24am
6-K
ddnrd0 bcefhyh6jtbz
2 May 22
Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study
8:15am
6-K
eb91vrr6 f5hx
27 Apr 22
Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
7:15am
6-K
13ft6l97cb
8 Apr 22
Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting
9:22am
6-K
t2dsuhxf59rde2qydy
8 Apr 22
Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
9:21am
6-K
je5m02c40c0ip tbe8z
10 Mar 22
Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
7:15am